Growth Factor News and Research

RSS

Compugen signs research and license agreement with a leading diagnostic company

Compugen Ltd. announced today that it has signed a research and license agreement with a leading diagnostic company covering CGEN-226, a novel biomarker candidate for early detection of preeclampsia.

5 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

Entest BioMedical files second patent application in the treatment of COPD

Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.

4 Nov 2009

Reduced VEGF can lead to degeneration of retina

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA).

4 Nov 2009

New improved enzyme could help facilitate spinal cord injuries

Researchers have developed an improved version of an enzyme that degrades the dense scar tissue that forms when the central nervous system is damaged. By digesting the tissue that blocks re-growth of damaged nerves, the improved enzyme - and new system for delivering it - could facilitate recovery from serious central nervous system injuries.

4 Nov 2009

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

BioMimetic Therapeutics, Inc. announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Hormone deficiency may be the cause for chronic diarrhoea

A common type of chronic diarrhoea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology.

3 Nov 2009

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

Ipsen announces sales highlights for the first nine months of 2009

Ipsen reported its sales for the third quarter and first nine months of 2009.

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

Regeneration of central nervous system axons can be achieved: Study

Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.

29 Oct 2009

First spinal surgery in the U.S. using Osteotech's MagniFuse PC bone graft technology performed

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that MagniFuse PC (Posterior Cervical) Bone Graft, a new tissue-based product built upon the Company's proprietary MagniFuse bone graft technology platform, has been used for the first time in a spinal surgery in the United States.

28 Oct 2009

Researchers show link between alcohol and cancer

Alcohol consumption has long been linked to cancer and its spread, but the underlying mechanism has never been clear.

27 Oct 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.

26 Oct 2009

Emodin raises hope for treatment of fibrotic liver diseases

In the last decade, advances in the understanding of genes promoting hepatic stellate cell (HSC) activation are impressive. However, there are few breakthroughs in therapeutic intervention of hepatic fibrogenesis. Efficient and well-tolerated antifibrotic drugs are lacking and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Research identifying innocuous antifibrotic agents is of high priority and urgently needed.

24 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Mother Nature has provided the lizard with a unique ability to regrow body tissue that is damaged or torn ― if its tail is pulled off, it grows right back. She has not been quite so generous with human beings. But we might be able to come close, thanks to new research from Tel Aviv University.

20 Oct 2009

Growth Factor News and Research

Compugen signs research and license agreement with a leading diagnostic company

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Entest BioMedical files second patent application in the treatment of COPD

Reduced VEGF can lead to degeneration of retina

New improved enzyme could help facilitate spinal cord injuries

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Hormone deficiency may be the cause for chronic diarrhoea

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Combination of inhibitor and antioxidants may help prevent diabetes complications

Ipsen announces sales highlights for the first nine months of 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

Regeneration of central nervous system axons can be achieved: Study

First spinal surgery in the U.S. using Osteotech's MagniFuse PC bone graft technology performed

Researchers show link between alcohol and cancer

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Emodin raises hope for treatment of fibrotic liver diseases

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News